Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum

Cancer Genetics

Volumn 205, Issue 11, 2012, Pages 594-598

  Nemoto, Hiroshi ^a   Tate, Genshu ^a   Kishimoto, Koji ^a   Saito, Mitsuo ^a   Shirahata, Atsushi ^a   Umemoto, Takehiro ^a   Matsubara, Taketo ^a   Goto, Tetsuhiro ^a   Mizukami, Hiroki ^a   Kigawa, Gaku ^a   Mitsuya, Toshiyuki ^a   Hibi, Kenji ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

E2F1; Heterozygous loss; Mesothelioma; NF2

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; PACLITAXEL;

ABDOMINAL DISTENSION; ABDOMINAL SURGERY; AGED; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CASE REPORT; CHECK2 GENE; CHROMOSOME 22Q; CHROMOSOME DELETION; CHROMOSOME DELETION 22Q; CONTROLLED STUDY; DEATH; DETERIORATION; FEMALE; FOLLOW UP; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IL17RA GENE; LAPAROSCOPY; MALIGNANT TRANSFORMATION; MONOSOMY; MONOSOMY 22; NEUROFIBROMATOSIS TYPE 2 GENE; OMENTECTOMY; PERITONEOCENTESIS; PERITONEUM MESOTHELIOMA; PERITONEUM METASTASIS; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SHANK3 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; WELL DIFFERENTIATED PAPILLARY MESOTHELIOMA OF THE PERITONEUM;

AGED; DNA MUTATIONAL ANALYSIS; E2F1 TRANSCRIPTION FACTOR; FATAL OUTCOME; FEMALE; GENES, NEUROFIBROMATOSIS 2; HISTOCYTOCHEMISTRY; HUMANS; LOSS OF HETEROZYGOSITY; MESOTHELIOMA; PERITONEAL NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84869419934     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.08.005     Document Type: Article

References (24)

1. Daya D., McCaughey W. Well-differentiated papillary mesothelioma of the peritoneum: a clinicopathologic study of 22 cases. Cancer 1990, 65:292-296.
2. Hoekstra A., Riben M., Frumovitz M., et al. Well-differentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature. Gynecol Oncol 2005, 98:161-167.
3. Clarke J.M., Helft P. Long-term survival of a woman with well differentiated papillary mesothelioma of the peritoneum: a case report and review of the literature. J Med Case Rep 2010, 4:346.
4. Malpica A., Sant'Ambrogio S., Deavers M.T., et al. Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases. Am J Surg Pathol 2012, 36:117-127.
5. Shukunami K., Hirabuki S., Kaneshima M., et al. Well-differentiated papillary mesothelioma involving the peritoneal and pleural cavities: successful treatment by local and systemic administration of carboplatin. Tumori 2000, 86:419-421.
6. Haba T., Wakasa K., Sasaki M. Well-differentiated papillary mesothelioma in the pelvic cavity. A case report. Acta Cytol 2003, 47:88-92.
7. Ikeda K., Suzuki T., Tate G., et al. Cytomorphologic features of well-differentiated papillary mesothelioma in peritoneal effusion: a case report. Diagn Cytopathol 2008, 36:512-515.
8. Hatano Y., Hirose Y., Matsunaga K., et al. Combined adenomatoid tumor and well differentiated papillary mesothelioma of the omentum. Pathol Int 2011, 61:681-685.
9. Cheng J.Q., Jhanwar S.C., Klein W.M., et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994, 54:5547-5551.
10. Illei P.B., Rusch V.W., Zakowski M.F., et al. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003, 9:2108-2113.
11. Bianchi A.B., Mitsunaga S.I., Cheng J.Q., et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 1995, 92:10854-10858.
12. Thurneysen C., Opitz I., Kurtz S., et al. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2009, 64:140-147.
13. Jensen D.E., Proctor M., Marquis S.T., et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998, 16:1097-1112.
14. Machida Y.J., Machida Y., Vashisht A.A., et al. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 2009, 284:34179-34188.
15. Misaghi S., Ottosen S., Izrael-Tomasevic A., et al. Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol 2009, 29:2181-2192.
16. Bott M., Brevet M., Taylor B.S., et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011, 43:668-672.
17. Testa J.R., Cheung M., Pei J., et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011, 43:1022-1025.
18. Tyagi S., Chabes A.L., Wysocka J., et al. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol Cell 2007, 27:107-119.
19. Yu W., Chan-On W., Teo M., et al. First somatic mutation of E2F1 in a critical DNA binding residue discovered in well-differentiated papillary mesothelioma of the peritoneum. Genome Biol 2011, 12:R96.
20. Tanida S., Kataoka H., Kubota E., et al. Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma. Int J Clin Oncol 2009, 14:266-269.
21. Nemoto H., Tate G., Schrinzi A., et al. Novel NF1 gene mutation in a Japanese patient with neurofibromatosis type 1 and a gastrointestinal stromal tumor. J Gastroenterol 2006, 41:378-382.
22. Hahn W.C., Weinberg R.A. Rules for making human tumor cells. N Eng J Med 2002, 347:1593-1603.
23. Knudson A.G. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001, 1:157-162.
24. Cheng J.Q., Lee W.C., Klein M.A., et al. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 1999, 24:238-242.